UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: **001-39777**

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]

On November 9, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated November 9, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nanobiotix S.A.
(Registrant)

Date: November 9, 2026

/s/ Brandon Owens
Brandon Owens
Vice President, Strategic Marketing and Corporate Communications

EXHIBIT 99.1

Nanobiotix to Participate in Investor Conferences in November

PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November:

Jefferies Global Healthcare Conference in London
Date: Monday, November 16, 2026
Presentation Time: 8:30am ET / 1:30pm GMT
Location: London (UK)
Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer

UBS Global Biopharma Conference
Date: Tuesday, November 17, 2026
Location: London (UK)

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter**.**

Nanobiotix

Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com

Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
joanne.choi@nanobiotix.com

Ricky Bhajun
Director, Investor Relations (EU)
+33 (0) 79 97 29 99
investors@nanobiotix.com

Media Relations

France – **HARDY**
Caroline Hardy
+33 06 70 33 49 50
carolinehardy@outlook.fr

Global – **uncapped**
Becky Lauer
+1 (646) 286-0057
uncappednanobiotix@uncappedcommunications.com

Attachment

- PR-20261109-November_Conference_Participation_2026 (https://ml.globenewswire.com/Resource/Download/f7e3a987-9233-41e9-96f4-c03a09120b5f)